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Abstract  Objective: To assess the sensitivity and specificity of ultrasound guided fine needle aspiration biopsy (FNAB) in renal tumors.  
 Methods: A diagnostic study was performed on 23 patients with renal tumors who visited the Urology Division, Department of Surgery, Dr. Hasan Sadikin General Hospital from January 2011 to August 2012. First time ultrasound guided was performed to the patients before nephrectomy. Renal tissues that were obtained from both procedures were examined histopathologically, and the result from nephrectomy was used as the gold standard. Analysis was 
conducted by measuring the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the ultrasound guided FNAB.   Results: The results showed that the sensitivity value of ultrasound guided 
FNAB was 85.71%, with 50% specificity, 94.74% PPV and 25% NPV. From 23 patients, only 2 patients had hematoma.  Conclusions: Ultrasound guided FNAB is sufficiently sensitive with a fair 
specificity for diagnosing renal tumors and is safe for patients.  Keywords: Renal tumor, sensitivity, specificity, ultasound guided FNAB 
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IntroductionRenal cell carcinoma (RCC) represents about 2–3% of all cancers with the highest incidence occurring in western countries. During the last two decades, there has been an increase in the incidence of approximately 2% per year  in Europe and throughout the world. Renal cell carcinoma is a solid tumor and  accounts for 
approximately 90% of all malignancies found in kidney.1 Nowadays in western countries, most  renal tumors (60%)  are found in early 
stage (less than 4 cm).2 Kidney tumors can be primary tumors or secondary tumors such as lymphoma.3In determining the histopathology of the tumor, a biopsy procedure is performed. Biopsy procedure comes in various types, including percutaneous biopsy and open biopsy. The percutaneous renal biopsy has been used for 
a long time, but it has  not been used anymore in the last decade  because of the low accuracy in retrieving tumor tissues.4–6 With further development of imaging equipments, such as ultrasound, Computerized Tomography scan (CT scan) and Magnetic Resonance Imaging (MRI), percutaneous biopsy is reused, albeit in combination with those equipments.2,3,5,7–9 Remzi and Marberger6 reported that biopsy 
using CT-scan guided fine-needle aspiration method in kidney tumors has the ability to 
predict the presence of 92–96% malignancy, 
67–70% grading of tumors, and 78–92% tumor’s subtype determination. A report from Reichelt et al.10 stated that ultrasound guided Fine Needle Aspiration Biopsi (FNAB) has an accuracy of 83.3% in predicting renal tumors. The use of ultrasound guided FNAB has many advantages when compared to CT-scan or MRI. In addition, ultrasound is cheaper and it does not involve radiation exposure. This ultrasound can be performed in real-time and is more readily available in hospitals, especially in Indonesia. The study was conducted to 
measure the sensitivity and specificity of the ultrasound guided FNAB for renal mass tumor. 
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MethodsA diagnostic study on 23 patients with renal tumors who visited the Urology Division of the Department of Surgery, Dr. Hasan Sadikin General Hospital was performed in the period of January 2011 to August 2012. Patients underwent ultrasound guided FNAB in the operating room shortly before nephrectomy. 
The procedure used 25G or 23G biopsy fine needle and the biopsy was performed once 
or twice until sufficient tumor tissues were obtained for histopathologic examination. The histopathologic examination was performed by two different pathologists. One examined the tumor tissues from the FNAB and the other examined the tumor tissues from the nephrectomy. The gold standard used was the histopathology results from the nephrectomy. The histopathology results that were obtained from both specimens were then compared and analyzed using 2x2 table diagnostic test 
consisting of sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) values.
Results
This study found that from 23 samples, 14 of 
them  were renal tumors with T4, followed by 6 with T3 and 3 with T2 (Table 1).
Table 1 Staging of  Renal Tumors
Stage FrequencyT1 0T2 3T3 6
T4 14
Total 23
Fine-needle biopsy can cause complications such as hematoma. In this study, there were 2 cases of hematoma out of 23 samples. 
The sensitivity was 85.71%, specificity was 
50%, PPV was 94.74% and NPV was 25% for ultrasound guided FNAB in this study (Table 2). Two cases with T2 and one case with T3 that were found negative for malignancy based on the ultrasound guided FNAB histopathologic results were positive based 
on the results of the surgery histopathologic 
results. On the contrary, one case with T4 that received positive result for malignancy based on the histopathologic results from ultrasound guided FNAB was negative based on the results of the surgery.
Table 2 Sensitivity, Specificity, Positive 
Predictive Value and Negative 
Predictive Value of Ultrasound 
Guided FNAB
Histopathologic 
FNAB
Histopathologic 
from Surgery
(Gold Standard) Total
Positive NegativePositive 18 1 19Negative 3 1 4
Total 21 2 23Sensitivity = 18/21 x 100 = 85.71%
Spesificity = ½ x 100  =  50%
Predicted positive value = 18/19 x 100  = 94.74%Negative predicted value = ¼ x 100          =  25%
DiscussionFine-needle biopsy can be used to avoid open-biopsy surgery for patients with high risk factors for surgery.2,4,6 This study found that the accuracy of the renal tumor diagnosis using ultrasound guided FNAB has a sensitivity of 85.71%. This means that the histopathologic results from ultrasound guided FNAB is 
sufficiently sensitive to diagnose malignancy. This is supported by the fact that this approach 
has a PPV of 94.74%. This is similar to the result found by Reichelt et al.10 that reported the accuracy of ultrasound guided FNAB for renal tumor of 83.3%, mainly for  a tumor 
of  less than 4 cm. Furthermore, the study 
found that the specificity of the ultrasound guided FNAB was 50% and the NPV was 25%, meaning that the ability of ultrasound guided FNAB to detect a negative results was only 50% and the percentage of true negative cases was 25%. Remzi and Marberger6  reported that 
CT-scan guided FNAB was able to predict 92–
96% malignancy, 67–70% grading the tumors, 
and 78–92% tumor’s subtype determination. Most patients came to the hospital at T3 stage 
or above. This situation influences the value of 
sensitivity and specificity of ultrasound guided FNAB. Based on this information, further 
Ultrasound Guided Fine Needle Aspiration Biopsy in Renal Tumors
:11–3
International Journal of Integrated Health Sciences. 2015;3(1) 13
studies should be conducted on patients with smaller tumors (less than T2). Fine needle aspiration biopsy can cause complications such as hematoma with an incidence of less than 5%.6,8,10 There are also other complications, such as pneumothorax, tumor seeding, arterial-venous malformation (AVM), and death.2,3,6 Malformation of the arterial venous occurred in less than 2% of  the cases and the mortality rate is 0.031%. Only 2 cases of hematoma were found in this study. 
This indicates that the use of the ultrasound guided FNAB for renal tumors is relatively safe.The ultrasound guided FNAB can be used to diagnose malignant kidney tumors. It can 
be used to obtain sufficient tumor tissues with no radiation effects. This approach is also affordable and a minimally invasive. Hence,it does not need general anesthesia and hospitalization.
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